Generic Medicine Info
Indications and Dosage
Adult: 7.5-15 mg at bedtime.
Elderly: Dosage adjustment may be required.
Renal Impairment
Dosage adjustment may be required.
Hepatic Impairment
Dosage adjustment may be required.
Severe respiratory failure. Children <15 years.
Special Precautions
Patient with respiratory disease, myasthenia gravis, depression, history of alcohol or substance use disorder, psychiatric or personality disorders, insomnia, and those who are at risk of falls. Debilitated patients. Avoid abrupt withdrawal. Renal and hepatic impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Anterograde amnesia, paradoxical reactions (e.g. hyperactive or aggressive behaviour), sleep-related activities (e.g. sleep-driving; cooking and eating food, and making phone calls while asleep).
Musculoskeletal and connective tissue disorders: Muscle hypotonia.
Nervous system disorders: Drowsiness, seizures.
Psychiatric disorders: Confusion, excitability, intoxicated feeling, irritability.
Skin and subcutaneous tissue disorders: Maculopapular rash.
Patient Counseling Information
This drug may cause CNS depression (e.g. drowsiness), if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor mental status, blood pressure, heart rate; respiratory, liver and renal functions (periodically with long-term therapy).
Drug Interactions
Potentiates the effects of CNS depressants including sedatives (e.g. tranquilisers, sleeping pills, opioid-containing cough or pain medications, antidepressants, neuroleptics), buprenorphine.
Food Interaction
Increased risk of drowsiness with alcohol; avoid concomitant use.
Description: Nordazepam is a long-acting benzodiazepine. It enhances the activity of GABA, a major inhibitory neurotransmitter in the brain, by binding to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS. This results in increased neuronal membrane permeability to chloride ions, leading to hyperpolarisation (a less excitable state) and stabilisation.
Absorption: Time to peak plasma concentration: 1.5 hours.
Distribution: Enters breast milk. Plasma protein binding: 97%.
Metabolism: Metabolised in the liver via hydroxylation to form oxazepam.
Excretion: Mainly via urine. Elimination half-life: Approx 65 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2997, Nordazepam. Accessed Feb. 23, 2022.

Store at room temperature.
MIMS Class
ATC Classification
N05BA16 - nordazepam ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Anon. Nordazepam. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 11/11/2021.

Buckingham R (ed). Nordazepam. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 11/11/2021.

Nordaz (Bouchara‚ÄźRecordati). MIMS Singapore. Accessed 11/11/2021.

Disclaimer: This information is independently developed by MIMS based on Nordazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in